CHEMO PHARMA LABORATORIES LTD. - 506365 - Declaration Of Non-Applicability Of Regulation 23(9) Of SEBI (LODR) Regulation, 2015
Declaration of Non-applicability of Regulation 23(9) of SEBI (LODR) Regulation, 201529-05-2023
29-05-2023
CHEMO PHARMA LABORATORIES LTD. - 506365 - Appointment Of M/S. Sarda Soni Associates LLP As An Internal Auditor For The Financial Year 2023-2024
Appointment of M/s. Sarda Soni Associates LLP as an Internal Auditor for the Financial Year 2023-202424-05-2023
CHEMO PHARMA LABORATORIES LTD. - 506365 - Appointment of Company Secretary and Compliance Officer
In accordance with the provisions of Regulation 30 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, attached herewith is the intimation of appointment of Company Secretary.24-05-2023
CHEMO PHARMA LABORATORIES LTD. - 506365 - Audited Financial Results Of The Company For The Quarter And Financial Year Ended March 31, 2023
Audited Financial Results of the Company for the quarter and Financial Year ended March 31, 202324-05-2023
CHEMO PHARMA LABORATORIES LTD. - 506365 - Board Meeting Outcome for Outcome Of The Board Meeting Held On May 24, 2023
Outcome of the Board Meeting held on May 24, 202324-05-2023
CHEMO PHARMA LABORATORIES LTD. - 506365 - Board Meeting Intimation for Intimation Of Board Meeting To Be Held On Wednesday, May 24, 2023
CHEMO PHARMA LABORATORIES LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 24/05/2023 ,inter alia, to consider and approve 1. To consider and approve the Audited Financial Results for the quarter and year ended March 31, 2023 along with the Auditor's Report thereon. 2. To consider appointment of M/s Sarda Soni & Associates as Internal Auditor of the Company for the financial year 2023-24 3. To consider appointment of Company Secretary and Compliance Officer of the Company.15-05-2023
CHEMO PHARMA LABORATORIES LTD. - 506365 - Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A
Format of Initial Disclosure to be made by an entity identified as a Large Corporate. Sr. No. Particulars Details 1Name of CompanyCHEMO PHARMA LABORATORIES LTD. 2CIN NO.L99999MH1942PLC003556 3 Outstanding borrowing of company as on 31st March / 31st December, as applicable (in Rs cr) 0.00 4Highest Credit Rating during the previous FY 0 4aName of the Credit Rating Agency issuing the Credit Rating mentioned in (4)Not Applicable 5Name of Stock Exchange# in which the fine shall be paid, in case of shortfall in the required borrowing under the frameworkBSE We confirm that we are a Large Corporate as per the applicability criteria given under the SEBI circular SEBI/HO/DDHS/CIR/P/2018/144 dated November 26, 2018. No Name of the Company Secretary: NIL Designation: ASHOK SOMANI COMPLIANCE OFFICER EmailId: chemopharmalab@gmail.com Name of the Chief Financial Officer: ASHOK GOVINDLAL SOMANI Designation: CFO EmailId: chemopharmalab@gmail.com Date: 29/04/2023 Note: In terms para of 3.2(ii) of the circular, beginning F.Y 2022, in the event of shortfall in the mandatory borrowing through debt securities, a fine of 0.2% of the shortfall shall be levied by Stock Exchanges at the end of the two-year block period. Therefore, an entity identified as LC shall provide, in its initial disclosure for a financial year, the name of Stock Exchange to which it would pay the fine in case of shortfall in the mandatory borrowing through debt markets.29-04-2023
CHEMO PHARMA LABORATORIES LTD. - 506365 - Compliances-Reg.24(A)-Annual Secretarial Compliance
Non-Applicability of Annual Secretarial Compliance Report for the year ended March 31, 2023 under Regulation 24A of SEBI (Listing Obligations and Disclosure Requirement) Regulations, 201517-04-2023
CHEMO PHARMA LABORATORIES LTD. - 506365 - Certificate Under Regulation 40(9) Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015 For The Year Ended March 31, 2023
We hereby submit Compliance Certificate under Regulation 40(9) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 for the year ended March 31, 202317-04-2023